Dual Targeting Multiwalled Carbon Nanotubes for Improved Neratinib Delivery in Breast Cancer

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2023 Aug 16

PMID 37583664

Authors

Amr Selim Abu Lila

Rohini Bhattacharya

Afrasim Moin

Turki Al Hagbani

Marwa Helmy Abdallah

Syed Mohd Danish Rizvi

El-Sayed Khafagy

Talib Hussain

Hosahalli Veerabhadrappa Gangadharappa

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to develop biotinylated chitosan (Bio-Chi) decorated multi-walled carbon nanotubes (MWCNTs) for breast cancer therapy with the tyrosine kinase inhibitor, neratinib (NT). For achieving such a purpose, carboxylic acid functionalized multiwalled carbon nanotubes (c-MWCNTs) were initially decorated non-covalently with biotin-chitosan (Bio-Chi) coating for achieving a dual targeting mode; pH-dependent release with chitosan and biotin-receptor mediated active targeting with biotin. Afterwards, Bio-Chi decorated c-MWCNTs were loaded with the tyrosine kinase inhibitor, neratinib (NT). The formulation was then characterized by dynamic light scattering, FTIR and EDX. The drug loading efficiency was estimated to be 95.6 ± 1.2%. drug release studies revealed a pH-dependent release of NT from Bio-Chi decorated c-MWCNTs, with a higher drug release under acidic pH conditions. Sulforhodamine B (SRB) cytotoxicity assay of different NT formulations disclosed dose-dependent cytotoxicities against SkBr3 cell line, with a superior cytotoxicity observed with NT-loaded Bio-Chi-coated c-MWCNTs, compared to either free NT or NT-loaded naked c-MWCNTs. The IC values for free NT, NT-loaded c-MWCNTs and NT-loaded Bio-Chi-coated c-MWCNTs were 548.43 ± 23.1 μg mL, 319.55 ± 17.9 μg mL, and 257.75 ± 24.5 μg mL, respectively. Interestingly, competitive cellular uptake studies revealed that surface decoration of drug-loaded c-MWCNTs with Bio-Chi permitted an enhanced uptake of c-MWCNTs by breast cancer cells, presumably, biotin receptors-mediated endocytosis. To sum up, Bio-Chi-decorated c-MWCNTs might be a promising delivery vehicle for mediating cell-specific drug delivery to breast cancer cells.

Citing Articles

Ligand-conjugated multiwalled carbon nanotubes for cancer targeted drug delivery.

Thakur C, Karthikeyan C, Ashby Jr C, Neupane R, Singh V, Jayachandra Babu R Front Pharmacol. 2024; 15:1417399.

PMID: 39119607 PMC: 11306048. DOI: 10.3389/fphar.2024.1417399.

References

Badea M, Balas M, Prodana M, Cojocaru F, Ionita D, Dinischiotu A . Carboxyl-Functionalized Carbon Nanotubes Loaded with Cisplatin Promote the Inhibition of PI3K/Akt Pathway and Suppress the Migration of Breast Cancer Cells. Pharmaceutics. 2022; 14(2). PMC: 8878903. DOI: 10.3390/pharmaceutics14020469. View

Brahmachari S, Ghosh M, Dutta S, Das P . Biotinylated amphiphile-single walled carbon nanotube conjugate for target-specific delivery to cancer cells. J Mater Chem B. 2020; 2(9):1160-1173. DOI: 10.1039/c3tb21334j. View

Yang W, Cheng Y, Xu T, Wang X, Wen L . Targeting cancer cells with biotin-dendrimer conjugates. Eur J Med Chem. 2008; 44(2):862-8. DOI: 10.1016/j.ejmech.2008.04.021. View

Ma H, Liu Y, Miao Z, Cheng S, Zhu Y, Wu Y . Neratinib inhibits proliferation and promotes apoptosis of acute myeloid leukemia cells by activating autophagy-dependent ferroptosis. Drug Dev Res. 2022; 83(7):1641-1653. DOI: 10.1002/ddr.21983. View

Darvishi M, Nomani A, Amini M, Shokrgozar M, Dinarvand R . Novel biotinylated chitosan-graft-polyethyleneimine copolymer as a targeted non-viral vector for anti-EGF receptor siRNA delivery in cancer cells. Int J Pharm. 2013; 456(2):408-16. DOI: 10.1016/j.ijpharm.2013.08.069. View

Tang L, Xiao Q, Mei Y, He S, Zhang Z, Wang R . Insights on functionalized carbon nanotubes for cancer theranostics. J Nanobiotechnology. 2021; 19(1):423. PMC: 8679967. DOI: 10.1186/s12951-021-01174-y. View

Mody N, Kumar Tekade R, Mehra N, Chopdey P, Jain N . Dendrimer, liposomes, carbon nanotubes and PLGA nanoparticles: one platform assessment of drug delivery potential. AAPS PharmSciTech. 2014; 15(2):388-99. PMC: 3969491. DOI: 10.1208/s12249-014-0073-3. View

Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M . Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022; 66:15-23. PMC: 9465273. DOI: 10.1016/j.breast.2022.08.010. View

Yao J, Liu J, Li Y, Li Y, Wu Q, Yang Y . HER2 positive bilateral metachronous primary breast carcinoma: A case report. Cancer Biol Ther. 2018; 19(5):349-354. PMC: 5915025. DOI: 10.1080/15384047.2018.1423916. View

10.

Ahmadi Nasab N, Hassani Kumleh H, Beygzadeh M, Teimourian S, Kazemzad M . Delivery of curcumin by a pH-responsive chitosan mesoporous silica nanoparticles for cancer treatment. Artif Cells Nanomed Biotechnol. 2017; 46(1):75-81. DOI: 10.1080/21691401.2017.1290648. View

11.

Pulkkinen M, Pikkarainen J, Wirth T, Tarvainen T, Haapa-aho V, Korhonen H . Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity. Eur J Pharm Biopharm. 2008; 70(1):66-74. DOI: 10.1016/j.ejpb.2008.04.018. View

12.

Liang L, Zhang Z, Kong Z, Liu Y, Shen J, Li D . Charge-tunable insertion process of carbon nanotubes into DNA nanotubes. J Mol Graph Model. 2016; 66:20-5. DOI: 10.1016/j.jmgm.2016.03.006. View

13.

Moin A, Wani S, Osmani R, Lila A, Khafagy E, Arab H . Formulation, characterization, and cellular toxicity assessment of tamoxifen-loaded silk fibroin nanoparticles in breast cancer. Drug Deliv. 2021; 28(1):1626-1636. PMC: 8330732. DOI: 10.1080/10717544.2021.1958106. View

14.

Ji S, Liu C, Zhang B, Yang F, Xu J, Long J . Carbon nanotubes in cancer diagnosis and therapy. Biochim Biophys Acta. 2010; 1806(1):29-35. DOI: 10.1016/j.bbcan.2010.02.004. View

15.

Dhillon S . Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU. Clin Drug Investig. 2019; 39(2):221-229. PMC: 6449300. DOI: 10.1007/s40261-018-0741-2. View

16.

Slepickova Kasalkova N, Slepicka P, Svorcik V . Carbon Nanostructures, Nanolayers, and Their Composites. Nanomaterials (Basel). 2021; 11(9). PMC: 8466887. DOI: 10.3390/nano11092368. View

17.

Azamjah N, Soltan-Zadeh Y, Zayeri F . Global Trend of Breast Cancer Mortality Rate: A 25-Year Study. Asian Pac J Cancer Prev. 2019; 20(7):2015-2020. PMC: 6745227. DOI: 10.31557/APJCP.2019.20.7.2015. View

18.

Tan J, Saifullah B, Kura A, Fakurazi S, Hussein M . Incorporation of Levodopa into Biopolymer Coatings Based on Carboxylated Carbon Nanotubes for pH-Dependent Sustained Release Drug Delivery. Nanomaterials (Basel). 2018; 8(6). PMC: 6027427. DOI: 10.3390/nano8060389. View

19.

Oh D, Bang Y . HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2019; 17(1):33-48. DOI: 10.1038/s41571-019-0268-3. View

20.

Sitia L, Sevieri M, Signati L, Bonizzi A, Chesi A, Mainini F . HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment. Cancers (Basel). 2022; 14(10). PMC: 9139811. DOI: 10.3390/cancers14102424. View